EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)

Bayer

Status: Completed

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)

Treatments: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

Study type: Observational

Funder types: Industry

Identifiers

NCT04516161

20977

Details and patient eligibility

About

In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels (metastatic castration-resistant prostate cancer, mCRPC). In addition researchers want to identify the factors which may contribute to survival over a long period of time in those patients. Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).

Enrollment: 1,180 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

• Adult patients with documented diagnosis of mCRPC (≥18 years at diagnosis), and
• Received Ra-223 as one of the therapies between Jan 1, 2013 and Jun 31, 2019 after diagnosis of mCRPC

Exclusion criteria

• Patients involved in clinical trials

Trial design

1,180 participants in 1 patient group

Radium-223 dichloride (Xofigo, BAY88-8223)

Description:

Patients with mCRPC who received treatment of Ra-223.

Treatment:

Drug: Radium-223 dichloride (Xofigo, BAY88-8223)